Branded versus Generic Clozapine for Treatment of Schizophrenia
Annals of Pharmacotherapy2003Vol. 37(3), pp. 350–353
Citations Over TimeTop 22% of 2003 papers
Eugene H. Makela, William D. Cutlip, James M. Stevenson, Jason Weimer, Ehab S Abdallah, Raja S Akhtar, Ahmed Aboraya, Erdoǵan Günel
Abstract
In this small group of patients with schizophrenia, no deterioration in clinical status in several domains was noted after changing from branded to generic clozapine. This finding is consistent with pharmacologic data suggesting bioequivalence of the 2 products. Results, however, must be interpreted cautiously due to the lack of optimal study controls and small sample size.
Related Papers
- → A new five factor model of schizophrenia(1994)241 cited
- → Positive and negative symptom profile schizophrenia and abnormalities in the P300 component of the event-related potential: a longitudinal controlled study(2004)32 cited
- → Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia(2022)2 cited
- → Efficiency of atypical antipsychotic in therapy schizophrenia(2011)
- Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging(2005)